Protection of human myeloid leukemic cells against doxorubicin-induced apoptosis by granulocyte-macrophage colony-stimulating factor and interleukin 3

Leukemia

Volumn 10, Issue 3, 1996, Pages 460-465

  Kaplinsky, C ^a   Lotem, J ^b   Sachs, L ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Doxorubicin; GM CSF and IL 3; Human myeloid leukemia; Protection from apoptosis

Indexed keywords

CYTOKINE; CYTOTOXIC AGENT; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MYELOID LEUKEMIA; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIZATION;

EID: 0029960946     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Sachs L. The molecular control of blood cell development. Science 1987; 238: 1374-1379.
2. Sachs L. The control of growth and differentiation in normal and leukemic blood cells. The 1989 Alfred P. Sloan Prize of the General Motors Cancer Research Foundation. Cancer 1990; 65: 2196-2206.
3. Sachs L. The adventures of a biologist. Prenatal diagnosis, hematopoiesis, leukemia, carcinogenesis, and tumor suppression. Adv Cancer Res 1995; 66: 1-40.
4. Sachs L, Lotem J Control of programmed cell death in normal and leukemic cells. New implications for therapy. Blood 1993; 82: 15-21.
5. Sachs L, Lotem J. Apoptosis in the hemopoietic system. In: Gregory CD (ed). Apoptosis and the Immune System. John Wiley and Sons: New York, 1995, pp 371-403.
6. Williams GT et al. Haemopoietic colony-stimulating factors promote cell survival by suppressing apoptosis. Nature 1990; 343: 76-79.
7. Lotem J, Cragoe EJ Jr, Sachs L. Rescue from programmed cell death in leukemic and normal myeloid cells. Blood 1991; 78: 953-960.
8. Griffin JD, Lowenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood 1986; 68: 1185-1195.
9. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
10. Yonish-Rouach E et al. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature 1991; 352: 345-347.
11. Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 1993; 82: 1092-1096.
12. Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 1992; 80: 1750-1757.
13. Lotem J, Sachs L. Interferon-γ inhibits apoptosis induced by wild-type p53, cytotoxic anti-cancer agents and viability factor deprivation in myeloid cells. Leukemia 1995; 9: 685-692.
14. Collins MKL, Marvel J, Malde P, Lopez-Rivas A. Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. J Exp Med 1992; 176: 1043-1051
15. Canman CE, Gilmer TM, Coutts SB, Kastan MB. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Develop 1995; 9: 600-611.
16. Löwenberg B, Touw IP. Hematopoietic growth factors and their receptors in acute leukemia. Blood 1993; 81: 281-292.
17. Wyllie AH. Glucocorticoid-induced tymocyte apoptosis is associated with endonuclease activation. Nature 1980; 284: 555-556.
18. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 1992; 80: 879-886.
19. Ashwell JD et al. Coming to terms with death: apoptosis in cancer and immune development. Immunol Today 1994; 15: 147-151.
20. Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dinners foil death wishes. Cell 1994; 79: 189-192.
21. Lowe SW et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-849.
22. Clarke AR et al. Thymocyte apoptosis induced by p53-dependent and -independent pathways. Nature 1993; 362: 849-852.
23. Lotem J, Sachs L. Regulation by bcl-2, c-myc and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation competent and defective myeloid leukemic cells. Cell Growth Differ 1993; 4: 41-47.
24. Lotem J, Sachs L. A mutant p53 antagonizes the deregulated c-myc mediated enhancement of apoptosis and decrease in leukemogenicity. Proc Natl Acad Sci USA 1995; 92: 9672-9676.
25. Cannistra SA, Groshek P, Griffin J. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effect of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989; 3: 328-334.
26. Miyauchi J et al. Growth factors influence the sensitivity of leukemic stem cells by cytosine arabinoside in culture. Blood 1989; 73: 1272-1278.
27. Tafuri A et al. Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs. Leukemia 1994; 8: 749-757.
28. Hunter AE et al. Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. Blood 1993; 82: 899-903.
29. Löwenberg B et al. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. New Engl J Med 1993; 328: 614-619.
30. Estey E. Use of colony-stimulating factors in the treatment of acute myeloid leukemia. Blood 1994; 83: 2015-2019.
31. Estey E et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose araC + daunorubicin: comparison to patients treated without GM-CSF. Blood 1992; 79: 2246-2255.
32. Bradbury D, Zhu Y-M, Russell N. Regulation of Bcl-2 expression and apoptosis in acute myeloblastic leukaemia cells by granulocyte-macrophage colony-stimulating factor. Leukemia 1994; 8: 786-791.
33. Fibach E, Sachs L. Control of normal differentiation of myeloid leukemic cells. XI. Induction of a specific requirement for cell viability and growth during differentiation of myelotd leukemic cells. J Cell Physiol 1976; 89: 259-266.
34. Vink A et al. Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 and its receptor. J Exp Med 1990; 172: 997-1000.
35. Klein B et al. Murine anti-interleukin 6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78: 1198-1204.
36. Koistmen P, Wang C, Curtis JE, McCulloch EA. Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from Ara-C toxicity. Leukemia 1991; 5: 789-795.
37. Dancescu M et al. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992; 176: 1319-1326.
38. Hardin J et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994; 84: 3063-3070.
39. Lichtenstein A et al. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995; 162: 248-255.
40. Baselga J et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibody. J Natl Cancer Inst 1993; 85: 1327-1333.
41. Lotem J, Sachs L. Control of sensitivity to induction of apoptosis in myeloid leukemic cells by differentiation and bcl-2 dependent and independent pathways. Cell Growth Differ 1994; 5: 321-327.
42. Lotem J, Sachs L. Regulation of bcl-2, bcl-XL and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone. Cell Growth Differ 1995; 6: 647-653.